July 3 (Reuters) - The U.S. Food and Drug Administration has declined to approve Amneal Pharmaceuticals' drug for Parkinson's disease that is designed to help control symptoms in patients for a longer duration, the company said on Monday.
(Reporting by Raghav Mahobe, Khushi Mandowara and Sriparna Roy in Bengaluru; Editing by Pooja Desai and Shweta Agarwal)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
These proven wealth builders could be exactly what you're searching for right now.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
Here's what could happen next to Microsoft shares.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
It's been an "everything buy bonds" bull rally in markets for months, but BofA is cautiously watching a couple of indicators.
The JPMorgan Nasdaq Equity Premium Income ETF offers a compelling blend of income and upside to my portfolio.
Nvidia and Super Micro Computer have been the best-performing S&P 500 stocks of 2024, but select Wall Street analysts still see substantial upside for shareholders.
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.